
Opinion|Videos|February 1, 2024
CheckMate 8HW: Nivolumab Plus Ipilimumab in MSI-High/dMMR Metastatic Colorectal Cancer
Following ASCO GI 2024, Pamela L. Kunz, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the CheckMate 8HW study investigating nivolumab plus ipilimumab in MSI-high/mismatch repair deficient metastatic colorectal cancer.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Reanalysis of Glioblastoma Vaccine Trial Suggests Larger Survival Benefit
2
FDA Accepts NDA for Mezigdomide Combination in Relapsed/Refractory Multiple Myeloma
3
Dostarlimab Demonstrates Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
4
What Long-Term Real-World Data on CAR T in Myeloma Could Reveal
5

































